Assyro AI

Orange Book product · Brand (NDA)

ADHANSIA XR

METHYLPHENIDATE HYDROCHLORIDE

Brand (NDA)NDA 212038DISCN KNOA PHARMA

At a glance

Feb 27, 2019

Approved

Brand (NDA)

Application

Not listed

TE code

12

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Feb 27, 2019

    7 yr 5 mo ago

  2. Today

  3. Patent 10111839 expires

    Listed method-of-use patent (U-2357) expiration.

    Oct 30, 2035

    in 9 yr 6 mo

  4. Patent 10292938 expires

    Listed drug product patent expiration.

    Oct 30, 2035

    in 9 yr 6 mo

  5. Patent 10292939 expires

    Listed drug product patent expiration.

    Oct 30, 2035

    in 9 yr 6 mo

  6. Patent 10449159 expires

    Listed method-of-use patent (U-2357) expiration.

    Oct 30, 2035

    in 9 yr 6 mo

  7. Patent 10500162 expires

    Listed method-of-use patent (U-2357) expiration.

    Oct 30, 2035

    in 9 yr 6 mo

  8. Patent 10507186 expires

    Listed drug product patent expiration.

    Oct 30, 2035

    in 9 yr 6 mo

  9. Patent 10512612 expires

    Listed drug product patent expiration.

    Oct 30, 2035

    in 9 yr 6 mo

  10. Patent 10512613 expires

    Listed method-of-use patent (U-2357) expiration.

    Oct 30, 2035

    in 9 yr 6 mo

  11. Patent 10568841 expires

    Listed drug product patent expiration.

    Oct 30, 2035

    in 9 yr 6 mo

  12. Patent 10688060 expires

    Listed drug product patent expiration.

    Oct 30, 2035

    in 9 yr 6 mo

  13. Patent 9974752 expires

    Listed drug product patent expiration.

    Oct 30, 2035

    in 9 yr 6 mo

  14. Patent 10722473 expires

    Listed method-of-use patent (U-2357) expiration.

    Nov 19, 2038

    in 12 yr 7 mo

Pharmaceutical detail

Active ingredient

METHYLPHENIDATE HYDROCHLORIDE

Strength

70MG

Dosage form

CAPSULE, EXTENDED RELEASE

Route

ORAL

TE code

Not listed

Application

NDA 212038

Product number

005

Marketing status

DISCN

Reference listed drug (RLD)

Yes

Reference standard (RS)

No

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (12)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
10111839Oct 30, 2035in 9 yr 6 mo
U-2357
10292938Oct 30, 2035in 9 yr 6 mo
Product
10292939Oct 30, 2035in 9 yr 6 mo
ProductU-2357
10449159Oct 30, 2035in 9 yr 6 mo
U-2357
10500162Oct 30, 2035in 9 yr 6 mo
U-2357
10507186Oct 30, 2035in 9 yr 6 mo
Product
10512612Oct 30, 2035in 9 yr 6 mo
Product
10512613Oct 30, 2035in 9 yr 6 mo
U-2357
10568841Oct 30, 2035in 9 yr 6 mo
ProductU-2357
10688060Oct 30, 2035in 9 yr 6 mo
Product
9974752Oct 30, 2035in 9 yr 6 mo
Product
10722473Nov 19, 2038in 12 yr 7 mo
U-2357
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.